{"id":"phxa41","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL1051","moleculeType":"Small molecule","molecularWeight":"432.60"},"_fixedAt":"2026-03-30T11:54:21.335034","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PhXA41 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"PhXA41 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:08.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["sideEffects","pubmed(28)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT05850936","phase":"NA","title":"Effect of IOP Lowering on Progressive HM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-01","conditions":"High Myopia, Intraocular Pressure","enrollment":152},{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":"Androgenic Alopecia","enrollment":420},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07425535","phase":"EARLY_PHASE1","title":"Optic Nerve Head Strain in Non-glaucoma Subjects","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT07412587","phase":"NA","title":"Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2015-07-08","conditions":"Androgenetic Alopecia (AGA), Telogen Effluvium, Female Pattern Hair Loss, Androgenic Alopecia","enrollment":29},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":489},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":138},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT04060758","phase":"PHASE1","title":"Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma","status":"COMPLETED","sponsor":"PolyActiva Pty Ltd","startDate":"2020-03-11","conditions":"Open Angle Glaucoma","enrollment":37},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT06449352","phase":"PHASE4","title":"Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost","status":"COMPLETED","sponsor":"Westlake Eye Specialists","startDate":"2024-06-13","conditions":"Normal Tension Glaucoma","enrollment":100},{"nctId":"NCT04500574","phase":"PHASE1","title":"Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2024-04-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":1},{"nctId":"NCT06993597","phase":"","title":"Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-09-01","conditions":"Glaucoma","enrollment":60},{"nctId":"NCT04630808","phase":"PHASE3","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-11-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":696},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT07048886","phase":"PHASE4","title":"Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Center for Sight Las Vegas","startDate":"2025-07-15","conditions":"Primary Open Angle Glaucoma","enrollment":68},{"nctId":"NCT04445519","phase":"PHASE3","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-06-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":691},{"nctId":"NCT06964191","phase":"PHASE2","title":"Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"PolyActiva Pty Ltd","startDate":"2025-05-31","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":75},{"nctId":"NCT07016113","phase":"PHASE2","title":"0.005% Latanoprost Gel for Nonsegmental Vitiligo","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-07-01","conditions":"Vitiligo - Macular Depigmentation","enrollment":10},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":204},{"nctId":"NCT06666855","phase":"PHASE3","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","status":"RECRUITING","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2024-11-28","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":338},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT05935527","phase":"PHASE1","title":"Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon","status":"COMPLETED","sponsor":"Peregrine Ophthalmic","startDate":"2023-04-28","conditions":"Lower Eyelid Steatoblepharon","enrollment":50},{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":"Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma","enrollment":36},{"nctId":"NCT06730516","phase":"EARLY_PHASE1","title":"Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT06629129","phase":"PHASE1","title":"Effect of Latanoprost on Optic Nerve Perfusion","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Treatment Outcome","enrollment":46},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT01704989","phase":"PHASE4","title":"The Laser in Pseudoexfoliation (LIP) Study","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2012-06","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT02801617","phase":"PHASE3","title":"Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":116},{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386},{"nctId":"NCT04761705","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"SUSPENDED","sponsor":"JeniVision, Inc.","startDate":"2021-03-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06239324","phase":"PHASE1, PHASE2","title":"Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser","status":"RECRUITING","sponsor":"Egymedicalpedia","startDate":"2024-02-01","conditions":"Alopecia Areata","enrollment":70},{"nctId":"NCT05333419","phase":"PHASE1","title":"Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","sponsor":"PolyActiva Pty Ltd","startDate":"2022-03-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":1},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":"Glaucoma","enrollment":136},{"nctId":"NCT02981446","phase":"PHASE3","title":"A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2017-01","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":370},{"nctId":"NCT00579969","phase":"PHASE2","title":"Comparison of Latanoprost Vs. Timolol","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2003-12","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT05495061","phase":"PHASE3","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":325},{"nctId":"NCT04957329","phase":"PHASE4","title":"Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-09-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":28},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT03697811","phase":"PHASE3","title":"DE-117 Spectrum 5 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Primary Open-angle Glaucoma and Ocular Hypertension","enrollment":107},{"nctId":"NCT04811326","phase":"PHASE4","title":"Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation","status":"UNKNOWN","sponsor":"Shaimaa Fawzy Abdel-rady Abdel-latif","startDate":"2021-01-13","conditions":"Non-segmental Vitiligo","enrollment":150},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT03657797","phase":"PHASE2","title":"Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2018-08-01","conditions":"Glaucoma, Open-Angle, Hypertension, Ocular","enrollment":656},{"nctId":"NCT01191008","phase":"","title":"Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":661},{"nctId":"NCT04405245","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2020-06-06","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":194},{"nctId":"NCT05864885","phase":"PHASE1","title":"Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-06-09","conditions":"Androgenetic Alopecia","enrollment":14},{"nctId":"NCT05790941","phase":"EARLY_PHASE1","title":"Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-03-11","conditions":"Hypotrichosis","enrollment":12},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":"Effect of Drug","enrollment":76},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":"Elevated Intraocular Pressure","enrollment":300},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT02585375","phase":"PHASE4","title":"Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-09-17","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT05299593","phase":"PHASE4","title":"24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.","status":"UNKNOWN","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2020-06-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":43},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03949244","phase":"PHASE4","title":"Nailfold Capillary Blood Flow With Latanoprost Bunod","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-08-15","conditions":"Glaucoma, Open-Angle","enrollment":47},{"nctId":"NCT00383019","phase":"PHASE3","title":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11-14","conditions":"Glaucoma, Ocular Hypertension","enrollment":300},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":"Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)","enrollment":300},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension","enrollment":50},{"nctId":"NCT00934089","phase":"PHASE2","title":"A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":31},{"nctId":"NCT00572455","phase":"PHASE2","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12-11","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":318},{"nctId":"NCT00947661","phase":"PHASE3","title":"Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2010-07","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":578},{"nctId":"NCT00486252","phase":"","title":"Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-06","conditions":"Glaucoma,Open-Angle, Ocular Hypertension","enrollment":996},{"nctId":"NCT01209624","phase":"","title":"Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-08","conditions":"Low Tension Glaucoma","enrollment":902},{"nctId":"NCT00950690","phase":"","title":"Efficacy and Tolerability of Xalatan in Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":1289},{"nctId":"NCT00143208","phase":"PHASE4","title":"Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT00159653","phase":"PHASE3","title":"A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":500},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":"Ocular Hypertension, Glaucoma, Open-angle Glaucoma","enrollment":436},{"nctId":"NCT00800267","phase":"PHASE3","title":"A Study of Glaucoma or Ocular Hypertension in Patients Within the United States","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-07","conditions":"Ocular Hypertension, Glaucoma","enrollment":418},{"nctId":"NCT00219596","phase":"PHASE3","title":"Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-06","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":240},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00230763","phase":"PHASE3","title":"Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-09","conditions":"Glaucoma, Primary Open Angle (POAG), Ocular Hypertension","enrollment":396},{"nctId":"NCT00277498","phase":"PHASE3","title":"A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":528},{"nctId":"NCT04743622","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost","status":"COMPLETED","sponsor":"CHA University","startDate":"2019-04-30","conditions":"Glaucoma, Ocular Hypertension","enrollment":57},{"nctId":"NCT04737928","phase":"NA","title":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2018-04-02","conditions":"Glaucoma, Primary Open Angle","enrollment":1},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT01265719","phase":"","title":"Long-Term Non-Interventional Latanoprost Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":175},{"nctId":"NCT00283764","phase":"PHASE3","title":"Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":""},{"nctId":"NCT00638742","phase":"PHASE1","title":"A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":375},{"nctId":"NCT00751049","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-12","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":294},{"nctId":"NCT00143429","phase":"PHASE2","title":"Corneal Versus Conjunctival Delivery Using a Delivery Device","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":""},{"nctId":"NCT01379144","phase":"PHASE2","title":"A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":282},{"nctId":"NCT00751062","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-11","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":267},{"nctId":"NCT00647101","phase":"PHASE4","title":"A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":600},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT00846989","phase":"PHASE1, PHASE2","title":"Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":276},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT01281020","phase":"","title":"Adherence With Fixed Versus Unfixed Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-05","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension, Exfoliation Glaucoma","enrollment":132},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Glaucoma, Open-Angle","enrollment":42},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"recentPublications":[{"date":"2006","pmid":"30000735","title":"Latanoprost.","journal":""},{"date":"1999 Mar","pmid":"10219468","title":"Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.","journal":"Arzneimittel-Forschung"},{"date":"1999 Mar","pmid":"10219467","title":"Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.","journal":"Arzneimittel-Forschung"},{"date":"1999 Mar","pmid":"10219466","title":"Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.","journal":"Arzneimittel-Forschung"},{"date":"1998 Mar-Apr","pmid":"9587840","title":"A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.","journal":"Japanese journal of ophthalmology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PhXA41","genericName":"PhXA41","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PhXA41 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}